Hematologist
CION Cancer Clinics
CML treatment milestones at 3, 6 and 12 months | CION Cancer Clinics
The widely used CML milestones are a BCR-ABL level of 10% IS or lower at 3 months, 1% or lower at 6 months, and 0.1% or lower at 12 months. Meeting them suggests your tablet is working. Missing one means your team looks for a reason, often missed doses or other medicines, before deciding whether the plan should change. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What are the CML milestones at months 3, 6 and 12?
- What is your team looking for at each check?
- What counts as on track, and what needs a closer look?
- What else affects whether a milestone is met?
- What do families often misunderstand about milestones?
- What can milestones not tell you?
- What should you take to each milestone review?
- Common questions about CML milestones
The short answer
What are the CML milestones at months 3, 6 and 12?
Widely used targets are a BCR-ABL level of 10% IS or lower at month 3, 1% or lower at month 6, and 0.1% or lower at month 12. Meeting them suggests the tablet is working as hoped. Missing one is a reason to look closer, not a verdict.
Why milestones exist
CML treatment runs for years. Milestones give you and your haematologist fixed points in the first year to check that the BCR-ABL level is falling fast enough. If it is not, there is time to find the reason and change course while the disease is still in chronic phase.
Guidelines differ a little
European and American expert groups use slightly different wording and cut-offs. Some treat a result above 10% at month 6 as the clearer sign of trouble, rather than a 1% target. Your team will say which they follow. The direction is the same everywhere: steadily down.
What the numbers need to be
These targets only apply to a quantitative BCR-ABL result on the International Scale (IS), from a laboratory that reports it reliably. A result without IS, or from a rare transcript type, may need to be read differently.
Reference methods and results differ between laboratories. A single result is always read alongside repeat tests and how you are doing.The first year
What is your team looking for at each check?
-
The first weeks
Blood counts are checked often. The aim is for white cells to fall and the spleen to shrink. This is called a haematological response, meaning the blood count has returned towards normal.
-
At month 3
The first key BCR-ABL test. A level of 10% IS or lower is the target. A higher result is usually repeated before any decision, and your team checks whether doses have been missed.
-
At month 6
A level of 1% IS or lower is the hoped-for result. A level still above 10% at this point is widely treated as a sign the tablet is not working well enough.
-
At month 12
The target is major molecular response, 0.1% IS or lower. A level above 1% at month 12 usually means the plan needs to change.
-
After the first year
The goal is to reach and keep major molecular response. Tests continue at regular gaps. A confirmed loss of that response at any time is taken seriously.
Not sure whether this applies to you?
Ask an oncologistSide by side
What counts as on track, and what needs a closer look?
Usually on track
Usually needs a closer look
Month 3: 10% IS or lower
Month 3: above 10%, repeated to confirm
Month 6: 1% IS or lower
Month 6: above 1%, and a clear concern if above 10%
Month 12: 0.1% IS or lower
Month 12: above 0.1%, and a clear concern if above 1%
Later: stays at 0.1% or lower
Later: a confirmed rise above 1%
Reading the result
What else affects whether a milestone is met?
A missed milestone always has a reason. Finding it comes before changing anything.
Taking the tablet every day
Even occasional missed doses can slow the fall in BCR-ABL. Cost, side effects and simple forgetting are all common reasons. Tell your team honestly, because each has a fix.
Other medicines and food
Some antacids, antibiotics, epilepsy medicines and herbal products change how much of a TKI reaches the blood. Some tablets must be taken away from food.
Bring to your review
- Every medicine you take
- Any ayurvedic or home remedy
Timing of the test
A test done a few weeks early or late can shift where you stand against a milestone. Your team reads the date along with the number.
The disease itself
Higher-risk features at diagnosis, or a gene mutation that lets CML resist the tablet, can slow the response. These are checked when a milestone is missed despite regular doses.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do families often misunderstand about milestones?
"We missed the 3-month target, so the tablet has failed."
Not on its own. A result just above target at month 3 is usually repeated, and many people reach later milestones on the same tablet. The trend matters more than one test.
"We reached 0.1%, so testing can stop."
Major molecular response is a milestone, not an end point. Regular tests continue, because a rise is easier to act on when it is caught early.
"A higher dose on our own will help us catch up."
Never change the dose yourself. It can cause serious side effects and hides the real reason for a slow response. Only your haematologist decides the dose.
"Everyone reaches the milestones at the same speed."
Responses vary. Some people reach deep responses early, others more slowly. Meeting targets on time is what counts, not matching someone else's numbers.
Being straight with you
What can milestones not tell you?
Milestones tell you whether the current treatment is doing its job. They cannot tell you how long you will live, and missing one does not set a fixed future. Many people who miss a target do well after the reason is found and the plan is changed.
Who these targets do not fit
The milestones here are for chronic phase CML on a first or second TKI. People diagnosed in accelerated phase or blast crisis, children, and people with rare transcript types may be judged against different goals. Your haematologist will tell you which apply.
How CION helps
CION's haematology team reads your results as a trend, checks for the usual reasons behind a slow response and presents your case at a tumour board when a change is being considered. Specialised tests are arranged with accredited laboratories.
If the cost of testing is the problem
Some families space out BCR-ABL tests because each one costs money and means a trip. That makes milestones hard to judge, and a slow response can go unnoticed for months. Tell your team if cost or travel is getting in the way. Schemes such as Aarogyasri, CGHS, ECHS, EHS and PM-JAY, or cashless insurance, may cover monitoring as part of an approved plan. Rules change, so check what applies to you now.
Before each review
What should you take to each milestone review?
- Every BCR-ABL report so far, in date order, with the lab name
- The date you started your current tablet
- A note of any missed or late doses, and why
- A list of all other medicines and remedies
- Side effects you have noticed, even small ones
- Your scheme or insurance card, if tests are covered
Questions we are asked
Common questions about CML milestones
My 3-month result was 12%. Should we worry?
It is just above the usual target, so it deserves attention, not panic. Your team will usually repeat the test, check for missed doses and look at other medicines. Many people in this position reach later milestones. Keep taking the tablet as prescribed until your haematologist advises otherwise.
Are milestones the same for every TKI?
Broadly, yes. The same targets are used whether you take imatinib or a newer TKI. Newer tablets may reach them sooner in some people, but that does not change what counts as on track. Your team may set a tighter goal if you hope to stop treatment one day.
What if my test was done late?
Tell your team the real start date and test date. A result taken some weeks late is read with that in mind. Try to keep future tests close to schedule, so the milestones stay meaningful.
Is a bone marrow test needed at a milestone?
Not usually, if the blood BCR-ABL test is reliable. A marrow test may be asked for when a milestone is missed, when blood counts behave oddly, or when the team suspects the disease is changing phase.
Does meeting every milestone mean I can stop the tablet?
Not by itself. Stopping is considered only after several years of treatment with deep responses held steadily, and with close monitoring available. It is a decision your haematologist makes with you. Never stop on your own.
Why does my doctor mention optimal and warning responses?
These are guideline terms. Optimal means on track. Warning means the result sits in a grey zone and needs closer watching. Failure means the plan should change. The label helps your team decide how quickly to act.
Can side effects make me miss a milestone?
Indirectly, yes. Side effects that lead to skipped doses or breaks can slow the response. Report them early. There are often ways to ease them, or another TKI may suit you better.
Can you review my results before my next milestone?
Yes. Send your BCR-ABL reports with dates and the name of your tablet. CION's haematology team will read them as a trend and explain where you stand. Call the helpline to arrange it.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- Leukemia & Lymphoma Society — Chronic Myeloid Leukemia
- National Cancer Institute — Chronic Myelogenous Leukemia Treatment (PDQ) - Patient Version
- American Cancer Society — Chronic Myeloid Leukemia (CML)
- Cancer.Net — Leukemia - Chronic Myeloid - CML
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
What Happens If You Miss a MilestoneThe steps your team takes after a missReading Your BCR-ABL Report and the IS ScaleHow to read the number behind each milestoneMajor Molecular Response ExplainedThe 12-month target in detailSwitching TKI: Reasons and What ChangesWhen a different tablet is considered
Talk to us
Unsure where your result stands?
Send us your BCR-ABL reports with dates. Our haematology team will read them as a trend and explain what they mean. One helpline serves every CION centre.